Advice When Considering Starting Statins First, always engage in a clinician-patient discussion of the potential for ASCVD risk reduction, adverse effects, drug-drug interactions, and patient preferences. Potential for adverse effects and drug-drug interactions. Management of other risk factors. Statin therapy is not routinely recommended for individuals with New York Heart Association class II to IV heart failure or who are receiving maintenance hemodialysis.
Acting on Data Deaths from cardiovascular disease increase globally while mortality rates decrease Western Europe and Central Europe are the only two of 21 regions where cardiovascular deaths and death rates have declined; Western sub-Saharan Africa and South Asia have seen increases SEATTLE — As the global population pushes past 7 billion and more people reach old age, the number of deaths from cardiovascular diseases is on the rise.
Cardiovascular diseases, the leading cause of premature death in the world, include heart attacks, strokes, and other circulatory diseases. At the same time, efforts to prevent and treat cardiovascular diseases appear to be working as the rise in deaths is slower than the overall growth of the population.
Death rates from cardiovascular diseases were steady or fell in every region of the world except Western sub-Saharan Africa, where the rates increased. Progress in fighting cardiovascular diseases is evident around the world but varies by region.
South Asia, which includes India, experienced the largest jump in total deaths due to cardiovascular diseases, with 1. In line with global trends, the increase in deaths from cardiovascular disease in India is driven by population growth and aging without the decrease in age-specific death rates found in many other countries.
Taken together as a region, the United States and Canada were among a small number of places with no detectable change in the number of deaths from cardiovascular diseases, because aging and population growth balanced out declines in age-specific death rates.
Two regions — Central Europe and Western Europe — have managed to do what their global peers have not by significantly reducing not only the death rates but also the total number of deaths from cardiovascular diseases, which fell by 5.
When looking at cardiovascular death rates, the high-income Asia Pacific region, which includes Japan, achieved the greatest decline globally. These demographic factors are not the only drivers behind the trend of increasing deaths and falling death rates.
Changes in the epidemiology of cardiovascular diseases is another factor. Several other types of cardiovascular causes of death followed the same pattern, including aortic aneurysm, hypertensive heart diseases, and endocarditis. Two conditions that were exceptions to this pattern are atrial fibrillation and peripheral vascular disease, for which deaths have jumped significantly sincedue to both higher death rates within specific age groups as well as general aging and population growth.
Researchers also examined whether wealthier countries fared better than lower-income countries when it comes to cardiovascular deaths and found there was not a strong correlation between income per capita and lower age-specific death rates.
The dramatic improvement in the death rates seen in some regions was attributed to prevention and treatment of cardiovascular diseases, in part by reducing risk factors including smoking. Primary care management of other risk factors for cardiovascular diseases, such as elevated blood pressure and blood sugar, are also important.
IHME makes this information widely available so that policymakers have the evidence they need to make informed decisions about how to allocate resources to best improve population health.Source: Chou R, Dana T, Blazina I, Daeges M, Jeanne TL.
Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. Demographic and epidemiologic drivers of global cardiovascular mortality Global deaths from cardiovascular disease are increasing as a result of population growth, the aging of populations, and epidemiologic changes in disease.
ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease . Heart (cardiovascular) disease (CVD, heart disease) is a variety of types of conditions that affect the heart, for example, coronary or valvular heart disease; cardiomyopathy, arrhythmias, and heart infections.
Symptoms of heart disease include chest pain, sweating, nausea, and shortness of breath. Treatment for heart disease includes . Supplement. eTable 1. Hazard Ratios and 95% Confidence Intervals of Composite Cardiovascular Disease, Congestive Heart Failure, Myocardial Infarction, and Stroke According to Quartile of Hour Urinary Sodium Excretion.
Reverse Heart Disease Now: Stop Deadly Cardiovascular Plaque Before It's Too Late [Stephen T. Sinatra, James C.
Roberts, Martin Zucker] on arteensevilla.com *FREE* shipping on qualifying offers. While most books focus solely on the role of cholesterol in heart disease, Reverse Heart Disease Now draws on new research that points to the .